Company News

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the …

Oxford Vacmedix feature in ‘Advancing Immunology’ Read More »

Oxford Vacmedix announces major manufacturing milestone for OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, …

Oxford Vacmedix announces major manufacturing milestone for OVM-200 Read More »

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford

New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of …

Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Read More »

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 …

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Read More »

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder …

OVM-200 Phase 1 Clinical Trial featured on TV Read More »

Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test

New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new …

Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Read More »

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix …

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays Read More »

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place

Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London …

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place Read More »

First patient treated with novel Cancer Vaccine

A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of …

First patient treated with novel Cancer Vaccine Read More »

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director

Appointment brings in-depth expertise of company development and investment and enhanced contacts in Asia to Oxford Vacmedix Press Release – Appointment of Mr Choon-Yoon Lim as Director Oxford 19th October 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mr. Chong-Yoon Lim as a …

Mr Chong-Yoon Lim of Hanmi Science appointed as a Director Read More »